Mindstate Design Labs Inc., a clinical-stage neuroengineering platform company, today announced the appointment of Graeme Bell as Independent Board Director. Graeme brings more than three decades of executive leadership experience scaling platform companies at the leading technological edge of the shift toward more programmable biology.
Graeme brings an exceptional track record of platform technology scaling, strategic execution, operational excellence, and private and public market navigation. He has served as Chief Financial Officer at leading biotech and AI companies, including Valo Health, Tmunity, Anacor Pharmaceuticals, and Intellia Therapeutics, and has also held senior executive positions at Merck & Co. Inc., including Global Head of Investor Relations and U.S. Chief Financial Officer. Graeme currently serves as Chief Financial Officer at Owkin, a leading agentic AI company for biotech applications.
“Graeme’s breadth of experience steering frontier biotech and AI companies has helped advance category-defining modalities from chemistry to cells, genes, and systems AI - each a new wave in the shift toward making biology programmable,” said Dillan DiNardo, CEO of Mindstate Design Labs. “He is uniquely suited to help us navigate our next chapter as we do the same for the psychoactive effects that have shown such incredible promise for numerous patient populations. We are thrilled to have Graeme’s insights as we push toward the phase of growth in our clinical, translational, and platform buildout.”
“I am delighted to join the board of Mindstate Design Labs at this exciting inflection,” said Graeme Bell. “The opportunity to contribute to a team that’s operating at the frontier of machine learning, neurophenomenology, and novel psychoactive drug classes is especially meaningful. I look forward to helping scale scientifically ambitious programs into transformative medicines.”
About Mindstate Design Labs
Mindstate Design Labs is a clinical-stage AI neuroengineering platform company developing novel classes of psychoactive therapeutics for psychiatric indications with high unmet need. The company’s Osmanthus platform maps the molecular biology underlying emotion, perception, and cognition to identify how specific neurotransmitter system interactions produce distinct emotional and cognitive states.
To learn more, visit www.mindstate.design and follow us on X and LinkedIn.
Contact Information
Inquiries can be directed to info@mindstate.design.